Publicacions - IR Sant Pau

Cercar

26/10/2023 Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis

Kwatra, SG, Yosipovitch, G, Legat, FJ, Reich, A, Paul, C, Simon, D, Naldi, L, Lynde, C, De Bruin-Weller, MS, Nahm, WK, Sauder, M, Gharib, R, Barbarot, S, Szepietowski, JC, Conrad, C, Fleischer, A, Laquer, VT, Misery, L, Serra-Baldrich, E, Lapeere, H, Ahmad, F, Lopez, ZKJ, Piketty, C, Ständer, S. Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis. NEW ENGLAND JOURNAL OF MEDICINE. 2023; 389(17)DOI:10.1056/NEJMoa2301333. PMID:37888917. IF:96.300(Q1/1D).

01/10/2023 The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.

Rivera-Díaz R, Pozo T, Alfageme F, Díaz Ley B, Osorio GF, Chico R, Vilarrasa E, Silvente C, Ciudad Blanco C, Romaní J, Martorell A, Fernández P, Romero Ferreiro C, Molina Leyva A. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.. Actas Dermo-Sifiliograficas. 2023; 114(9)DOI:10.1016/j.ad.2023.06.018. PMID:37479135. IF:(Q/D).

14/09/2023 Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review

Girolomoni, G, Savage, L, Gisondi, P, Svensson, A, Mahe, E, Augustin, M, Puig, L. Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review. Dermatology and Therapy. 2023; DOI:10.1007/s13555-023-01014. PMID:. IF:3.500(Q1/3D).

01/09/2023 Statins and psoriasis: Position statement by the Psoriasis Task Force of the European Society of Dermatology and Venerology

Gonzalez-Cantero, A, Boehncke, WH, De Sutter, J, Zamorano, JL, Lambert, J, Puig, L. Statins and psoriasis: Position statement by the Psoriasis Task Force of the European Society of Dermatology and Venerology. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37(9)DOI:10.1111/jdv.19191. PMID:37259959. IF:8.500(Q1/1D).

01/09/2023 Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

Berenguer-Ruiz S., Aparicio-Domínguez M., Herranz-Pinto P., Ruíz-Villaverde R., López-Ferrer A., Santos-Juanes J., Rodríguez Fernández-Freire L., Hospital-Gil M., Arias-Santiago S., Carretero-Hernández G., Mateu-Puchades A., Ferran M., del Alcázar E., Santos-Alarcón S., Garcia-Latasa de Aranibar F.J., Belinchón-Romero I., González-Cantero Á., Ruíz-Genao D., Eiris-Salvado N., Rocamora-Durán V., Rivera-Diaz R., de la Cueva P., Daudén E., Salgado-Boquete L., Llamas-Velasco M.. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; DOI:10.1111/jdv.19468. PMID:37625815. IF:8.500(Q1/1D).

01/09/2023 Epidermolysis bullosa acquisita induced by atezolizumab

Carmona-Rocha E., Aguado M., Tubau C., Sánchez S., Mozos A., Sullivan I., Spertino J.. Epidermolysis bullosa acquisita induced by atezolizumab. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. 2023; DOI:10.1111/ddg.15203. PMID:37658659. IF:5.600(Q1/1D).

23/08/2023 Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: the first septennium

Carmona-Rocha, E, Puig, L. Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: the first septennium. Immunotherapy. 2023; 15(15)DOI:10.2217/imt-2023-0013. PMID:37609785. IF:2.700(Q3/7D).

23/08/2023 Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA)

Pereyra-Rodríguez J.J., Poveda J.L., Rivero A., Serra-Baldrich E., Silvestre J.F., Armario-Hita J.C., Calleja M.Á., Carrascosa J.M., Flórez Á., Herranz P., Comellas M., Ortiz de Frutos F.J.. Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA). JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; DOI:10.1111/jdv.19432. PMID:37594914. IF:8.500(Q1/1D).

04/08/2023 The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases

Navarro-Compán V., Puig L., Vidal S., Ramírez J., Llamas-Velasco M., Fernández-Carballido C., Almodóvar R., Pinto J.A., Galíndez-Aguirregoikoa E., Zarco P., Joven B., Gratacós J., Juanola X., Blanco R., Arias-Santiago S., Sanz Sanz J., Queiro R., Canete, JD. The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases. Frontiers in Immunology. 2023; 14DOI:10.3389/fimmu.2023.1191782. PMID:37600764. IF:5.700(Q1/3D).

01/08/2023 Psoriasis: a focus on upcoming oral formulations

Rusinol, L, Carmona-Rocha E., Puig L.. Psoriasis: a focus on upcoming oral formulations. EXPERT OPINION ON INVESTIGATIONAL DRUGS. 2023; 32(7)DOI:10.1080/13543784.2023.2242767. PMID:37507233. IF:4.900(Q1/2D).

12/07/2023 Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population

Sahuquillo-Torralba A., Hospital-Gil M., Vilarrasa-Rull E., Llamas-Velasco M., Rivera R., Carrascosa J.M., de la Cueva-Dovao P., Armesto-Santos S., Ruíz-Villaverde R., Velasco-Pastor M., Magdaleno-Tapial J., Yanguas-Bayona J.I., Ribera-Pibernat M., Salgado-Boquete L., Herranz-Pinto P., Romero-Mate A., Martínez-Lorenzo E., López-Estebaranz J.L., Ballescá-López F., Botella-Estrada R.. Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population. AUSTRALASIAN JOURNAL OF DERMATOLOGY. 2023; DOI:10.1111/ajd.14130. PMID:37435962. IF:2.200(Q2/5D).

03/07/2023 A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis

Kirkham, BW, Egeberg, A, Behrens, F, Pinter, A, Merola, JF, Holzkaemper, T, Gallo, G, Ng, KJ, Bolce, R, Schuster, C, Nash, P, Puig, L. A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis. Rheumatology and Therapy. 2023; 10(5)DOI:10.1007/s40744-023-00553-1. PMID:37400681. IF:2.900(Q2/4D).

01/07/2023 Pradiktive Faktoren fur Anti-MDA5-Antikorper bei Patienten mit Dermatomyositis: eine retrospektive multizentrische Studie

Castellanos-Gonzalez, M, Bris, BB, Marsol, IB, Campos, MM, Ruiz-Villaverde, R, Llorente, CP, Nuno-Gonzalez, A, Sanchez, JT, Mur, EC, Garcia, RG, Alonso, AB, Espanol, GA, Garcia, YH, Schmidt, JMS, Sanchez, MA, Crespo, ER, Alonso, ED, Gallo-Pineda, G, Izquierdo, JAA, Varillas-Delgado, D. Pradiktive Faktoren fur Anti-MDA5-Antikorper bei Patienten mit Dermatomyositis: eine retrospektive multizentrische Studie. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. 2023; 21(7)DOI:10.1111/ddg.15089_g. PMID:37427730. IF:5.600(Q1/1D).

01/07/2023 Sonidegib as a Locally Advanced Basal Cell Carcinoma Therapy in Real-life Clinical Setting: A National Multicentre Study

Moreno-Arrones, OM, Bea-Ardebol, S, Mayo-Martinez, F, Perez-Pastor, G, Torres-Navarro, I, Bonfill-Orti, M, Deza, G, Ruiz-Salas, V, Masferrer, E, Feal, C, Turrion-Merino, L, Toll, A, Yebenes, M, Galiano-Mejias, S, Jaka, A, Ferrandiz-Pulido, C, Florez, A, Hernandez-Hernandez, N, Fernandez-de-Misa, R, Rios-Buceta, L, Sanmartin, O. Sonidegib as a Locally Advanced Basal Cell Carcinoma Therapy in Real-life Clinical Setting: A National Multicentre Study. Actas Dermo-Sifiliograficas. 2023; 114(7)DOI:10.1016/j.ad.2023.06.011. PMID:37302483. IF:(Q/D).

01/07/2023 Sonidegib as a Locally Advanced Basal Cell Carcinoma Therapy in Real-life Clinical Setting: A National Multicentre Study.

Moreno-Arrones OM, Béa-Ardebol S, Mayo-Martinez F, Pérez-Pastor G, Torres-Navarro I, Bonfill-Ortí M, Deza G, Ruiz-Salas V, Masferrer E, Feal C, Turrión-Merino L, Toll A, Yébenes M, Galiano-Mejías S, Jaka A, Ferrandiz-Pulido C, Florez A, Hernández-Hernández N, Fernández-de-Misa R, Rios-Buceta L, Sanmartin O. Sonidegib as a Locally Advanced Basal Cell Carcinoma Therapy in Real-life Clinical Setting: A National Multicentre Study.. Actas Dermo-Sifiliograficas. 2023; 114(7)DOI:10.1016/j.ad.2023.04.022. PMID:37088285. IF:(Q/D).

21/06/2023 Dermoscopic features of trichoepithelioma: A multicentre observational case-control study conducted by the International Dermoscopy Society

Longo C., Lippolis N., Lai M., Spadafora M., Kaleci S., Condorelli A.G., Lombardi M., Pampena R., Argenziano G., Nazzaro G., Scalvenzi M., Akay B.N., Broganelli P., Fargnoli M.C., Paoli J., Yélamos O., Pellacani G., Borsari S., Lallas A.. Dermoscopic features of trichoepithelioma: A multicentre observational case-control study conducted by the International Dermoscopy Society. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37(10)DOI:10.1111/jdv.19262. PMID:37326166. IF:8.500(Q1/1D).

13/06/2023 Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice

Costanzo A., Llamas-Velasco M., Fabbrocini G., Cuccia A., Rivera-Diaz R., Du Jardin, KG, Kasujee I., Puig L., Carrascosa J.M.. Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37(10)DOI:10.1111/jdv.19229. PMID:37246505. IF:8.500(Q1/1D).

09/06/2023 EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis

Zabotti, A, De Marco, G, Gosset, L, Baraliakos, X, Aletaha, D, Iagnocco, A, Gisondi, P, Balint, PV, Bertheussen, H, Boehncke, WH, Damjanov, NS, de Wit, M, Errichetti, E, Marzo-Ortega, H, Protopopov, M, Puig, L, Queiro, R, Ruscitti, P, Savage, L, Schett, G, Siebert, S, Stamm, TA, Studenic, P, Tinazzi, I, Van den Bosch, FE, van der Helm-van Mil, A, Watad, A, Smolen, JS, McGonagle, DG. EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. ANNALS OF THE RHEUMATIC DISEASES. 2023; 82(9)DOI:10.1136/ard-2023-224148. PMID:37295926. IF:20.300(Q1/1D).

01/06/2023 Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies

Sanchez-Rodriguez, G, Puig, L. Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023; 24(12)DOI:10.3390/ijms241210305. PMID:37373452. IF:4.900(Q1/3D).

31/05/2023 Real-world experience with vismodegib on advanced and multiple BCCs: data from the RELIVIS study

Ruiz-Salas, V, Podlipnik, S, Sandoval-Clavijo, A, Sanmartin-Jimenez, O, Bernia-Petit, E, Bonfill-Orti, M, Bassas-Freixas, P, Yebenes-Marsal, M, Florez-Menendez, A, Sola-Ortigosa, J, Just-Sarobe, M, Aguayo-Ortiz, RS, Niubo, EMI, Quintana-Codina, M, Deza, G, Jaka, A, Fuentes, MJ, Canueto, J, Toll, A. Real-world experience with vismodegib on advanced and multiple BCCs: data from the RELIVIS study. DERMATOLOGY. 2023; 239(5)DOI:10.1159/000530813. PMID:37257423. IF:3.000(Q2/4D).

02/05/2023 A multicenter case-control study comparing sun exposure habits and use of photoprotection measures in patients diagnosed with different types of skin cancer

Navarro-Bielsa A., Gracia-Cazaña T., Almagro M., De la Fuente-Meira, S, Florez Á., Yélamos O., Montero-Vilchez T., González-Cruz C., Diago A., Abadías-Granado I., Fuentelsaz V., Colmenero M., Banuls, J, Arias-Santiago S., Buendía-Eisman A., Almenara-Blasco M., Gil-Pallares P., Gilaberte Y.. A multicenter case-control study comparing sun exposure habits and use of photoprotection measures in patients diagnosed with different types of skin cancer. PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE. 2023; 39(5)DOI:10.1111/phpp.12878. PMID:37130164. IF:2.500(Q2/4D).

01/05/2023 Common Approach to Metabolic-Associated Fatty Liver Disease in Patients With Psoriasis: Consensus-Based Recommendations From a Multidisciplinary Group of Experts

Carrascosa, JM, Vilarrasa, E, Belinchon, I, Herranz, P, Crespo, J, Guimera, F, Olveira, A. Common Approach to Metabolic-Associated Fatty Liver Disease in Patients With Psoriasis: Consensus-Based Recommendations From a Multidisciplinary Group of Experts. Actas Dermo-Sifiliograficas. 2023; 114(5)DOI:10.1016/j.ad.2023.01.004. PMID:36720362. IF:(Q/D).

20/04/2023 Nonadherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey

Quirke-McFarlane, S, Weinman, J, Cook, ES, Yiu, ZZN, Dand, N, Langan, SM, Bechman, K, Tsakok, T, Mason, KJ, McAteer, H, Meynell, F, Coker, B, Vincent, A, Urmston, D, Vesty, A, Kelly, J, Lancelot, C, Moorhead, L, Barbosa, IA, Bachelez, H, Capon, F, Contreras, CR, De La Cruz, C, Di Meglio, P, Gisondi, P, Jullien, D, Lambert, J, Naldi, L, Puig, L, Spuls, P, Torres, T, Warren, RB, Waweru, H, Galloway, JB, Griffiths, CEM, Barker, JN, Norton, S, Smith, CH, Mahil, SK. Nonadherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey. BRITISH JOURNAL OF DERMATOLOGY. 2023; 188(5)DOI:10.1093/bjd/ljac144. PMID:36763806. IF:11.000(Q1/1D).

05/04/2023 Development and validation of a model to predict complex Mohs micrographic surgery in clinical practice: REGESMOSH scale

Montero-Vilchez, T, Garces, JR, Rodriguez-Prieto, MA, Ruiz-Salas, V, de Eusebio-Murillo, E, Minano-Medrano, R, Escutia-Munoz, B, Gonzalez-Sixto, B, Artola-Igarza, JL, Alfaro-Rubio, A, Redondo, P, Delgado-Jimenez, Y, Sanchez-Schmidt, JM, Allende-Markixana, I, Alonso-Pacheco, ML, Garcia-Bracamonte, B, de la Cueva-dobao, P, Navarro-Tejedor, R, Ciudad-Blanco, C, Carnero-Gonzalez, L, Vazquez-Veiga, H, Cano-Martinez, N, Vilarrasa, E, Sanchez-Sambucety, P, Lopez-Estebaranz, JL, Botella-Estrada, R, Feal-Cortizas, JC, Martorell-Calatayud, A, Gil, P, Morales-Gordillo, V, Toll-Abello, A, Ocerin-Guerra, I, Mayor-Arenal, M, Suarez-Fernandez, R, Sainz-Gaspar, L, Descalzo, MA, Garcia-Doval, I, Sanmartin-Jimenez, O. Development and validation of a model to predict complex Mohs micrographic surgery in clinical practice: REGESMOSH scale. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37(8)DOI:10.1111/jdv.19056. PMID:36950898. IF:8.500(Q1/1D).

01/04/2023 Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV): Data for the First 5 Years

Falkenhain-Lopez, D, Muniesa, C, Estrach, MT, Morillo-Andujar, M, Penate, Y, Acebo, E, Pujol, RM, Garcia-Muret, MP, Machan, S, Medina, S, Botella-Estrada, R, de Misa, RF, Blanes, M, Florez, A, Perez-Paredes, G, Izu, R, Yanguas, I, Silva-Diaz, E, Perez-Ferriols, A, Prieto-Torres, L, Zayas, A, Parera-Amer, ME, Perez, A, Aspe, L, Roman, C, Sanchez-Caminero, MP, Bassas-Vila, J, Dominguez-Aunon, JD, Calzado, L, Navedo, M, Ortiz-Prieto, A, Servitje, O, Polo-Rodriguez, I, Torres, I, Hernandez-Hernandez, MN, Mitxelena-Eceiza, J, Garcia-Vazquez, A, Garcia-Doval, I, Ortiz-Romero, PL. Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV): Data for the First 5 Years. Actas Dermo-Sifiliograficas. 2023; 114(4)DOI:10.1016/j.ad.2022.11.013. PMID:36848951. IF:(Q/D).

15/03/2023 Exploring the potential of artificial intelligence in improving skin lesion diagnosis in primary care

Escale-Besa, A, Yelamos, O, Vidal-Alaball, J, Fuster-Casanovas, A, Catalina, QM, Borve, A, Aguilar, RAE, Fusta-Novell, X, Cubiro, X, Rafat, ME, Lopez-Sanchez, C, Marin-Gomez, FX. Exploring the potential of artificial intelligence in improving skin lesion diagnosis in primary care. Scientific Reports. 2023; 13(1)DOI:10.1038/s41598-023-31340-1. PMID:36922556. IF:3.800(Q1/2D).

10/03/2023 Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes (vol 9, 1092688, 2023)

Egeberg A., Merola J.F., Schaekel, K, Puig L., Mahar P.D., Wang I.Y., Pavo I., Schuster C., Griffiths, CEM. Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes (vol 9, 1092688, 2023). Frontiers in Medicine. 2023; 10DOI:10.3389/fmed.2023.1171132. PMID:36974067. IF:3.100(Q1/2D).

22/02/2023 Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials

Kokolakis, G, Warren, RB, Strober, B, Blauvelt, A, Puig, L, Morita, A, Gooderham, M, Korber, A, Vanvoorden, V, Wang, M, de Cuyper, D, Madden, C, Gomez, NN, Lebwohl, M. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials. BRITISH JOURNAL OF DERMATOLOGY. 2023; 188(3)DOI:10.1093/bjd/ljac089. PMID:36751950. IF:11.000(Q1/1D).

01/02/2023 BAP1-inactivated Melanocytic Tumor: Dermoscopic Features to Aid Diagnosis

Fusta-Novell, X, Garcia-Herrera, A, Yelamos, O. BAP1-inactivated Melanocytic Tumor: Dermoscopic Features to Aid Diagnosis. Actas Dermo-Sifiliograficas. 2023; 114(2)DOI:10.1016/j.ad.2021.10.022. PMID:36216154. IF:(Q/D).

01/01/2023 Bimekizumab in the Treatment of Plaque Psoriasis Focus on Patient Selection and Perspectives

Camina-Conforto, G, Mateu-Arrom L., López-Ferrer A., Puig L.. Bimekizumab in the Treatment of Plaque Psoriasis Focus on Patient Selection and Perspectives. Patient Preference and Adherence. 2023; 17DOI:10.2147/PPA.S350760. PMID:37408843. IF:2.000(Q2/4D).

01/01/2023 Real-World Treatment Patterns, Resource Use and Costs in Adult Patients With Atopic Dermatitis Receiving Systemic Treatment: Derma-Atopic Study in Spain

Artime E., Serra E., Mert C., Díaz-Cerezo S., Huete T., Hernández-Subirá I., Lledo-Bryant L., Sicras-Mainar A.. Real-World Treatment Patterns, Resource Use and Costs in Adult Patients With Atopic Dermatitis Receiving Systemic Treatment: Derma-Atopic Study in Spain. Actas Dermo-Sifiliograficas. 2023; 114(1)DOI:10.1016/j.ad.2022.08.025. PMID:36368579. IF:(Q/D).

01/01/2023 Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial

Strober B., Paul C., Blauvelt A., Thaçi D., Puig L., Lebwohl M., White K., Vanvoorden V., Deherder D., Gomez N.N., Eyerich K.. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2023; 89(3)DOI:10.1016/j.jaad.2023.04.063. PMID:37182701. IF:12.800(Q1/1D).

01/01/2023 PsoBarrier EU study: a Multicentre, Cross-sectional Survey Investigating the Quality of Psoriasis Care in Four European Countries

Langenbruch A., Mohr N., Andrees V., Kessens I., Reich A., Czarnecka-Operacz M., Puig L., Dauden E., Iversen L., Augustin M.. PsoBarrier EU study: a Multicentre, Cross-sectional Survey Investigating the Quality of Psoriasis Care in Four European Countries. ACTA DERMATO-VENEREOLOGICA. 2023; 103DOI:10.2340/actadv.v103.6532. PMID:37649411. IF:3.500(Q1/3D).

01/01/2023 Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results

Pereyra-Rodríguez J.-J., Herranz P., Ruiz-Villaverde R., Elosua-González M., Galán-Gutiérrez M., Figueras-Nart I., Miquel J., de la Cueva P., Serra-Baldrich E., Munera-Campos M., Melé-Ninot G., Expósito-Serrano V., Perez B., Serrano A., Ortiz de Frutos J.F., Armario-Hita J.C.. Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results. CLINICAL AND EXPERIMENTAL DERMATOLOGY. 2023; 48(9)DOI:10.1093/ced/llad153. PMID:37098171. IF:3.700(Q1/2D).

01/01/2023 Genetic and Epigenetic Mechanisms of Psoriasis

Mateu-Arrom L., Puig L.. Genetic and Epigenetic Mechanisms of Psoriasis. Genes. 2023; 14(8)DOI:10.3390/genes14081619. PMID:37628670. IF:2.800(Q2/5D).

01/01/2023 The biological basis of disease recurrence in psoriasis

Carmona-Rocha E., Puig L.. The biological basis of disease recurrence in psoriasis. Italian Journal of Dermatology and Venereology. 2023; 158(4)DOI:10.23736/S2784-8671.23.07583-7. PMID:37404193. IF:1.800(Q3/6D).

01/01/2023 Diversity in the clinical presentation of generalized pustular psoriasis (GPP): A series of case vignettes from around the world

Choon S.E., Elewski B.E., Fujita H., Geng S., van de Kerkhof P., Mburu S., Puig L., Romiti R., Venturini M.. Diversity in the clinical presentation of generalized pustular psoriasis (GPP): A series of case vignettes from around the world. EXPERIMENTAL DERMATOLOGY. 2023; 32(8)DOI:10.1111/exd.14794. PMID:36999936. IF:3.500(Q1/3D).

01/01/2023 Predictive factors for anti-MDA5 antibody in patients with dermatomyositis: a retrospective multicenter study

Castellanos-Gonzalez M., Bris B.B., Marsol I.B., Campos M.M., Ruiz-Villaverde R., Llorente C.P., Nuno-Gonzalez A., Sánchez J.T., Mur E.C., García R.G., Alonso A.B., Español G.A., García Y.H., Schmidt J.M.S., Sánchez M.A., Crespo E.R., Alonso E.D.L.H., Gallo-Pineda G., Izquierdo J.A.A., Varillas-Delgado D.. Predictive factors for anti-MDA5 antibody in patients with dermatomyositis: a retrospective multicenter study. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. 2023; 21(7)DOI:10.1111/ddg.15089. PMID:37218533. IF:5.600(Q1/1D).

01/01/2023 Prognostic factors for satellitosis or in-transit metastasis in cutaneous squamous cell carcinoma: A multicentric cohort study

Marti-Marti I., Podlipnik S., Cañueto J., Ferrándiz-Pulido C., Deza G., Sanmartín O., Jaka A., Beà-Ardèbol S., Botella-Estrada R., Redondo P., Turrión-Merino L., Ruiz-Salas V., Masferrer E., Yébenes M., Sánchez-Schmidt J.-M., Gracia-Darder I., Altemir-Vidal A., Aguayo-Ortiz R.S., Becerril S., Bodet-Castillo D., Leal L., Fuente M.J., Moreno-Arrones O.M., Abril-Pérez C., Tomás-Velázquez A., Sandoval-Clavijo A., Toll A.. Prognostic factors for satellitosis or in-transit metastasis in cutaneous squamous cell carcinoma: A multicentric cohort study. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2023; 89(1)DOI:10.1016/j.jaad.2023.02.048. PMID:36907554. IF:12.800(Q1/1D).

01/01/2023 [Translated article] Updated Position of the Spanish Psoriasis Group (GPs) on the Use of Biosimilar Drugs in Moderate to Severe Psoriasis [Actualización en el posicionamiento del Grupo Español de Psoriasis (GPS) en la utilización de medicamentos biosimilares en psoriasis moderada-grave]

Ruiz-Villaverde R., Galán-Gutiérrez M., Llamas-Velasco M., Salgado-Boquete L., Puig L., de la Cueva P., Carrascosa J.M.. [Translated article] Updated Position of the Spanish Psoriasis Group (GPs) on the Use of Biosimilar Drugs in Moderate to Severe Psoriasis [Actualización en el posicionamiento del Grupo Español de Psoriasis (GPS) en la utilización de medicamentos biosimilares en psoriasis moderada-grave]. Actas Dermo-Sifiliograficas. 2023; 114(6)DOI:10.1016/j.ad.2023.02.022. PMID:37172891. IF:(Q/D).